LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today reported results from a previously-announced double-blind, placebo-controlled clinical trial in healthy volunteers indicating that its drug candidate arimoclomol was safe and well-tolerated at a dose of 400 mg administered orally three times daily throughout the 28-day trial period.
